Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 161

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 161
---
 is no established market for the resale of these shares, the Selling Stockholders may sell the shares registered for the resale in this Resale Offering at the fixed price of $1.00 per share.  Once, and if, our Common Stock is upgraded to the OTCQB tier of OTC Market, or on any national security exchange and there is an established market for these resale shares, the Selling Stockholders may sell the resale shares from time to time at the market price prevailing market prices or in negotiated transactions or a combination of such methods of sale directly or through brokers.                         |
| Use of Proceeds                                                                                                                                                              |     | We will not receive any proceeds from the sale of the Common Stock in the Resale Offering by the Selling Stockholders. However, to the extent that the common stock purchase warrants held by the Selling Stockholders are exercised for cash, we will receive the payment of the exercise price in connection with such exercise.                                                                                                                                                                                                                                                                                                      |
| Risk Factors                                                                                                                                                                 |     | See the discussion under the caption “Risk Factors” and other information in this Prospectus for a discussion of factors you should carefully consider before deciding to invest in our Common Stock.                                                                                                                                                                                                                                                                                                                                                                                                                                   |

| (1) | As of February 14, 2025 |

| (2) | The                                                                                                                                             
 number of shares of our Common Stock that will be outstanding after this Offering is based on 60,729,100 shares of our Common Stock outstanding 
 as of February 14, 2025 and excludes:                                                                                                           |

| ● | 4,960,000 shares of Common                                                                                                            
 stock issuable upon the exercise of outstanding stock options as of February __, 2025, granted pursuant to our Global Share Incentive 
 Plan (2021), as amended (the “2021 Plan”), at a weighted-average exercise price of $0.31 per share and                                |

| ● | 2,240,000 shares of Common                                                                                       
 Stock reserved, in the aggregate, for future issuance under our 2021 Plan, as amended, as of February  14, 2025. |

| ● | 6,372,265 shares of Common                                                                                          
 stock issuable upon the exercise of 6,372,265 warrants, at a weighted-average exercise price of $1.16 per share and |

Except as otherwise indicated, all information in this Prospectus:

<div align='center'>Alt-1

[RESALE PROSPECTUS ALTERNATE PAGE]

SELLING STOCKHOLDERS</